MX2019005670A - Secuelas de lesion pulmonar inducida por baipas cardiopulmonar. - Google Patents
Secuelas de lesion pulmonar inducida por baipas cardiopulmonar.Info
- Publication number
- MX2019005670A MX2019005670A MX2019005670A MX2019005670A MX2019005670A MX 2019005670 A MX2019005670 A MX 2019005670A MX 2019005670 A MX2019005670 A MX 2019005670A MX 2019005670 A MX2019005670 A MX 2019005670A MX 2019005670 A MX2019005670 A MX 2019005670A
- Authority
- MX
- Mexico
- Prior art keywords
- cardiopulmonary bypass
- sequelae
- induced pulmonary
- pulmonary injury
- injury
- Prior art date
Links
- 208000004852 Lung Injury Diseases 0.000 title abstract 2
- 230000002612 cardiopulmonary effect Effects 0.000 title abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010018910 Haemolysis Diseases 0.000 abstract 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 abstract 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 abstract 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 abstract 1
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 abstract 1
- 229960002173 citrulline Drugs 0.000 abstract 1
- 235000013477 citrulline Nutrition 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 230000008588 hemolysis Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Surgery (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Lubricants (AREA)
- Amplifiers (AREA)
- Medicinal Preparation (AREA)
Abstract
Un método para administrar citrulina a un paciente durante la cirugía sin filtración de la hemólisis para reducir el desacoplamiento del dímero de la enzima eNOS que conduce a lesión pulmonar inducida por baipás cardiopulmonar.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662439772P | 2016-12-28 | 2016-12-28 | |
| PCT/US2017/068698 WO2018125999A1 (en) | 2016-12-28 | 2017-12-28 | Sequelae of cardiopulmonary bypass-induced pulmonary injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019005670A true MX2019005670A (es) | 2019-08-12 |
Family
ID=62710740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019005670A MX2019005670A (es) | 2016-12-28 | 2017-12-28 | Secuelas de lesion pulmonar inducida por baipas cardiopulmonar. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10265286B2 (es) |
| EP (1) | EP3506892B1 (es) |
| JP (1) | JP7236384B2 (es) |
| KR (1) | KR102327069B1 (es) |
| CN (1) | CN109922799B (es) |
| AR (1) | AR110663A1 (es) |
| AU (2) | AU2017388398A1 (es) |
| BR (1) | BR112019007245A2 (es) |
| CA (1) | CA3048432A1 (es) |
| CO (1) | CO2019007188A2 (es) |
| IL (2) | IL300046A (es) |
| MX (1) | MX2019005670A (es) |
| RU (1) | RU2762593C2 (es) |
| WO (1) | WO2018125999A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230404956A1 (en) * | 2022-06-21 | 2023-12-21 | Asklepion Pharmaceuticals Llc | Therapeutic window for citrulline therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346382B1 (en) | 1999-06-01 | 2002-02-12 | Vanderbilt University | Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto |
| US9486429B2 (en) | 1999-06-01 | 2016-11-08 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
| CN101083589B (zh) | 2007-07-13 | 2010-08-11 | 华为技术有限公司 | 无源光网络中的终端检测认证方法、装置及操作管理系统 |
| CN104083352A (zh) | 2008-01-31 | 2014-10-08 | 范德比尔特大学 | 对于肺部病症的治疗 |
| CA2990279C (en) | 2015-06-29 | 2022-07-05 | Vanderbilt University | Intravenous administration of citrulline during surgery |
-
2017
- 2017-12-22 US US15/853,248 patent/US10265286B2/en active Active
- 2017-12-27 AR ARP170103691A patent/AR110663A1/es unknown
- 2017-12-28 IL IL300046A patent/IL300046A/en unknown
- 2017-12-28 CN CN201780069489.XA patent/CN109922799B/zh active Active
- 2017-12-28 CA CA3048432A patent/CA3048432A1/en active Pending
- 2017-12-28 WO PCT/US2017/068698 patent/WO2018125999A1/en active Application Filing
- 2017-12-28 KR KR1020197015117A patent/KR102327069B1/ko active IP Right Grant
- 2017-12-28 MX MX2019005670A patent/MX2019005670A/es unknown
- 2017-12-28 BR BR112019007245A patent/BR112019007245A2/pt active Search and Examination
- 2017-12-28 RU RU2019123427A patent/RU2762593C2/ru active
- 2017-12-28 AU AU2017388398A patent/AU2017388398A1/en not_active Abandoned
- 2017-12-28 JP JP2019534922A patent/JP7236384B2/ja active Active
- 2017-12-28 EP EP17887010.1A patent/EP3506892B1/en active Active
-
2019
- 2019-06-27 IL IL267707A patent/IL267707A/en unknown
- 2019-07-03 CO CONC2019/0007188A patent/CO2019007188A2/es unknown
-
2024
- 2024-02-15 AU AU2024200984A patent/AU2024200984A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019123427A (ru) | 2021-01-29 |
| CO2019007188A2 (es) | 2019-07-31 |
| CN109922799A (zh) | 2019-06-21 |
| EP3506892A4 (en) | 2020-05-06 |
| AR110663A1 (es) | 2019-04-17 |
| RU2762593C2 (ru) | 2021-12-21 |
| KR20190101363A (ko) | 2019-08-30 |
| JP7236384B2 (ja) | 2023-03-09 |
| WO2018125999A1 (en) | 2018-07-05 |
| KR102327069B1 (ko) | 2021-11-16 |
| AU2017388398A1 (en) | 2019-05-23 |
| BR112019007245A2 (pt) | 2019-07-02 |
| RU2019123427A3 (es) | 2021-05-20 |
| EP3506892B1 (en) | 2024-05-15 |
| JP2020503326A (ja) | 2020-01-30 |
| CA3048432A1 (en) | 2018-07-05 |
| CN109922799B (zh) | 2021-11-16 |
| US20180214403A1 (en) | 2018-08-02 |
| EP3506892A1 (en) | 2019-07-10 |
| IL300046A (en) | 2023-03-01 |
| AU2024200984A1 (en) | 2024-03-07 |
| IL267707A (en) | 2019-08-29 |
| US10265286B2 (en) | 2019-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016502256A1 (en) | Medical use | |
| IL272444A (en) | Compounds, their salts and methods for treating diseases | |
| PH12017500933A1 (en) | Sublingual administration of riluzole | |
| PH12017500934A1 (en) | Sublingual formulation of riluzole | |
| PH12018501237A1 (en) | Isoindole compounds | |
| PH12019500725A1 (en) | Methods of treating acute kidney injury | |
| SA517390475B1 (ar) | نظام أكياس متعددة وطريقة لتحضير مكونات الدم | |
| EA033446B1 (ru) | Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта | |
| MX2017015664A (es) | Administracion intravenosa de citrulina durante cirugia. | |
| TW201613639A (en) | Methods for treating cardiovascular diseases | |
| IL289544A (en) | Methods for administering anti-fibrotic therapy | |
| EP3549582A3 (en) | Novel capsazepine analogs for the treatment of cancer and other proliferative diseases | |
| MX2019005670A (es) | Secuelas de lesion pulmonar inducida por baipas cardiopulmonar. | |
| MY198753A (en) | Treatment of androgen deprivation therapy associated symptoms | |
| MX2019014090A (es) | Métodos para el tratamiento de la reservoritis crónica. | |
| PL3431119T3 (pl) | Aparat do pozaustrojowego oczyszczania krwi | |
| IL248428A0 (en) | Use of 3,1-propanedisulfonic acid or pharmaceutically acceptable saline to treat sarcoidosis | |
| GB201812861D0 (en) | Methods of administering therapy | |
| HK1225969A1 (zh) | 利用低劑量的拉喹莫德治療克隆氏病 | |
| CY1124271T1 (el) | Παραγοντας αγωγης της δερματομυκωσης που περιλαμβανει κιτρικο τρικαλιο | |
| PL3609486T3 (pl) | Sarpogrelat do zastosowania w sposobie leczenia choroby serca u ssaków | |
| UA104030U (uk) | Спосіб лікування хворих із загостренням хронічного бронхіту вірусної етіології | |
| TH1501007280A (th) | สูตรผสมที่ใช้ทางปากสำหรับการบำบัดโรคหัวใจและระบบหมุนเวียนโลหิต (Cardiovascular Diseases) | |
| GEP20207079B (en) | Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine | |
| UA92810U (uk) | Спосіб лікування шизоафективного розладу |